newsfilter
← Latest News
Business Wire·

Ra Pharmaceuticals Announces Selection for the First ALS Platform Trial by the Sean M. Healey & AMG Center for ALS at Mass General

BOSTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the selection of zilucoplan as one of the first clinical candidates to be evaluated in a pioneering platform trial for amyotrophic lateral sclerosis (ALS), led by the Sean M. Healey & AMG Center for ALS at Mass General. The Healey Center has agreed to provide funding for the execution of the platform trial to support its goal of accelerating the development of effective treatments for patients with ALS.